O. Secchi, A. Franchi, and A. Lunello, “Comments to ‘Cost per responder for vedolizumab and ustekinumab in Crohn’s disease patients after failure of TNF-α inhibitors in Italy’”, AboutOpen, vol. 10, no. 1, pp. 82–86, Jun. 2023.